PT  - JOURNAL ARTICLE
AU  - Pierre-Yves Courand
AU  - Géraldine Pina Jomir
AU  - Chahéra Khouatra
AU  - Christian Scheiber
AU  - Ségolène Turquier
AU  - Jean-Charles Glérant
AU  - Bénédicte Mastroianni
AU  - Béatrice Gentil
AU  - Anne-Sophie Blanchet-Legens
AU  - Alfred Dib
AU  - Geneviève Derumeaux
AU  - Marc Humbert
AU  - Jean-François Mornex
AU  - Jean-François Cordier
AU  - Vincent Cottin
TI  - Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension
AID  - 10.1183/09031936.00158014
DP  - 2015 Jan 01
TA  - European Respiratory Journal
PG  - 139--149
VI  - 45
IP  - 1
4099  - http://erj.ersjournals.com/content/45/1/139.short
4100  - http://erj.ersjournals.com/content/45/1/139.full
SO  - Eur Respir J2015 Jan 01; 45
AB  - Right ventricle ejection fraction (RVEF) evaluated with magnetic resonance imaging is a strong determinant of patient outcomes in pulmonary arterial hypertension. We evaluated the prognostic value of RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change 3–6 months after initiating pulmonary arterial hypertension-specific therapy. In a prospective cohort of newly diagnosed patients with idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension, RVEF was measured at baseline (n=100) and 3–6 months after initiation of therapy (n=78). After a median follow-up of 4.1 years, 41 deaths occurred, including 35 from cardiovascular causes. Patients with a (median) baseline RVEF >25% had better survival than those with a RVEF <25% using Kaplan–Meier analysis (p=0.010). RVEF at baseline was an independent predictor of all-cause and cardiovascular mortality in adjusted Cox regression model (p=0.002 and p=0.007, respectively; HR 0.93 for both). Patients with stable or increased RVEF at 3–6 months had a trend for improved all-cause survival (HR 2.43, p=0.086) and had less cardiovascular mortality (HR 3.25, p=0.034) than those in whom RVEF decreased despite therapy. RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change in RVEF 3–6 months after therapy initiation independently predict outcomes in patients with pulmonary arterial hypertension. RVEF assessed with CPERA at baseline, and its changes on therapy, independently predict outcome in patients with PAH http://ow.ly/DsCS4